February 11, 2019
Before we can solve the problems of patient engagement, we have to make sure we’re not the ones creating them. That was one takeaway of Geisinger CIO Karen Murphy’s remarks at the HIMSS Patient Engagement and Experience Summit in Orlando this morning.
“We’re trying to innovate because […] patient engagement and patient experience is truly not ideal,” she said. “We have the system arranged so that...
Photo by Douglas Sacha (Getty)
January 31, 2019
Duke University has received about $500,000 in grant money from Blue Cross Blue Shield of North Carolina to build an app designed to help doctors and patients work together to prevent opioid abuse.
The investment is part of $2 million in grants distributed earlier this week by Blue Cross NC across five organizations tackling the opioid crisis in different ways, which in turn is part of a $10...
October 25, 2018
In one of the few and far between bipartisan bills to be passed during this administration, President Donald Trump signed into law yesterday a new package aimed to help tackle the opioid epidemic, called the Support for Patients and Communities Act.
The latest legislation expands opioid-specific telemedicine services, exempting the technology from certain requirements. It also modifies the...
October 19, 2018
WEconnect, maker of an app that helps addiction patients through their first year after substance abuse treatment, announced yesterday that it has closed a $6.05 million Series A round.
Investors in the company include ServiceNow founder Fred Luddy, Buckingham Capital Management Chairman Larry Leeds Jr., Metalab founder Andrew Wilkinson, CEO of Venturehouse Mark Ein, and others.
The app — which...
October 4, 2018
Yesterday the senate overwhelmingly passed a new opioid bill in a 98-1 vote, with only Senator Mike Lee (R-UT) voting against it and Senator Ted Cruz (R-TX) not voting. The vote expands telemedicine services to people with opioid abuse disorder, exempting it from certain requirements. It also modifies the provisions regarding electronic prescriptions and post-surgical pain management.
The panel will include a discussion with ‘Do No Harm’ documentary filmmaker Robyn Simon. Credit: Screen snap of film Do No Harm
August 23, 2018
Eight years ago, Eliza CEO Alex Drane came up with the idea for “The Unmentionables,” an annual panel at Health 2.0 where participants would address difficult but important topics in healthcare.
“Her bullet point was that there are things in healthcare that drive health outcomes that we don’t mention,” Health 2.0 cofounder and CEO Indu Subaiya told MobiHealthNews. “She started with topics like...
April 26, 2018
This Saturday, the United States Drug Enforcement Agency (DEA) will host its third National Prescription Drug Take Back Day. And this time, Google is helping out.
The search engine company and tech giant announced in a blog post yesterday that it would implement several features to support the DEA's efforts to combat the opioid crisis, starting with a Google Maps-based locator tool to help...
January 5, 2018
Although generations of Americans have struggled with opioid addiction, what was once seen as a peripheral drug problem has lately hit the American public with force. Opioid overdoses have become so common that they are the number one cause of injury-related deaths in the United States, according to CDC reports. In 2015 alone opioids were involved in 33,091 deaths, according to the agency. The...
December 11, 2017
Last week, the HHS' opioid crisis code-a-thon concluded with presentations by nine of the 50 teams that participated. Three of these teams were chosen as the competition's winners, and will receive $10,000 to further develop their ideas.
“When the government holds a code-a-thon, there’s an admission in society that we have hit a roadblock, that we need help, and we go out to the polity to help us...
October 18, 2017
Pear Therapeutics announced today that reSET-O, a digital therapeutic for opioid use disorder, has received an Expedited Access Pathway (EAP) designation from the FDA. The EAP designation doesn't mean that the FDA has cleared the product, only that it has committed to fast-tracking it through the clearance process because of its timely public health value.
“The opioid epidemic continues to...